文献速递流行病学与生物统计真实世界研究与卫生经济新药、器械与细胞基因治疗研发

美国注射吸毒者HIV预防组合方案的成本效果估算:基于模型的分析

Estimation of the cost-effectiveness of HIV prevention portfolios for people who inject drugs in the United States: A model-based analysis.
PubMed 文献 · PLoS Med · 2017-05-24

研究采用经经验校准的动态分区模型,评估阿片类激动剂治疗(OAT)、针具与注射器项目(NSP)、HIV检测与治疗(Test & Treat)及口服HIV暴露前预防(PrEP)单用或联用20年的成本效果。50%覆盖的OAT、NSP和Test & Treat单用具有成本效果,PrEP单用成本效果不佳。联合扩展OAT、NSP和Test & Treat至50%覆盖可具成本效果。

要点

  • 50%覆盖的OAT、NSP和Test & Treat单用相对下一最高覆盖水平具成本效果。
  • 50%覆盖的PrEP每获得QALY成本US$300,000,单用不具成本效果。
  • 联合扩展OAT、NSP、Test & Treat至50%覆盖可具成本效果。

核心结论

  • 估计OAT、NSP和Test & Treat单用或联用有潜力有效且具成本效果地预防美国注射吸毒者的HIV。
  • 基于所评估情景,PrEP在该人群中不太可能具成本效果。

研究设计与样本

  • 采用经经验校准的动态分区模型,评估四种干预单用及联用20年时间 horizon 的成本效果。
  • 模型参数来自文献、已发表模型和专家意见。

主要发现

  • 20年内50%覆盖的OAT最多可避免22,000例感染,每获得QALY成本US$18,000。
  • 50%覆盖的NSP最多可避免35,000例感染,每获得QALY成本US$25,000。
  • 50%覆盖的Test & Treat最多可避免6,700例感染,每获得QALY成本US$27,000。
  • 50%覆盖的PrEP最多可避免37,000例感染,每获得QALY成本US$300,000。
  • 概率敏感性分析中59%的组合优先增加OAT、41%优先增加NSP,PrEP不太可能成为优先或具成本效果的补充。

关键数值与推荐

  • OAT、NSP和Test & Treat单用扩展至50%覆盖相对下一最高覆盖水平(低、中、高分别为40%、45%、50%)可具成本效果。
  • 联合扩展OAT、NSP、Test & Treat至50%覆盖相对下一最佳组合每获得QALY成本可低于US$50,000。

局限性

  • 研究结果为示意性,因可达到的覆盖水平数据有限,实践中扩展情景可能超出可行水平。
  • 假设干预独立且规模报酬不变。
  • 动态分区模型限制了结构敏感性探索。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The risks of HIV transmission associated with the opioid epidemic make cost-effective programs for people who inject drugs (PWID) a public health priority. Some of these programs have benefits beyond prevention of HIV-a critical consideration given that injection drug use is increasing across most United States demographic groups. To identify high-value HIV prevention program portfolios for US PWID, we consider combinations of four interventions with demonstrated efficacy: opioid agonist therapy (OAT), needle and syringe programs (NSPs), HIV testing and treatment (Test & Treat), and oral HIV pre-exposure prophylaxis (PrEP). METHODS AND FINDINGS: We adapted an empirically calibrated dynamic compartmental model and used it to assess the discounted costs (in 2015 US dollars), health outcomes (HIV infections averted, change in HIV prevalence, and discounted quality-adjusted life years [QALYs]), and incremental cost-effectiveness ratios (ICERs) of the four prevention programs, considered singly and in combination over a 20-y time horizon. We obtained epidemiologic, economic, and health utility parameter estimates from the literature, previously published models, and expert opinion. We estimate that expansions of OAT, NSPs, and Test & Treat implemented singly up to 50% coverage levels can be cost-effective relative to the next highest coverage level (low, medium, and high at 40%, 45%, and 50%, respectively) and that OAT, which we assume to have immediate and direct health benefits for the individual, has the potential to be the highest value investment, even under scenarios where it prevents fewer infections than other programs. Although a model-based analysis can provide only estimates of health outcomes, we project that, over 20 y, 50% coverage with OAT could avert up to 22,000 (95% CI: 5,200, 46,000) infections and cost US$18,000 (95% CI: US$14,000, US$24,000) per QALY gained, 50% NSP coverage could avert up to 35,000 (95% CI: 8,900, 43,000) infections and cost US$25,000 (95% CI: US$7,000, US$76,000) per QALY gained, 50% Test & Treat coverage could avert up to 6,700 (95% CI: 1,200, 16,000) infections and cost US$27,000 (95% CI: US$15,000, US$48,000) per QALY gained, and 50% PrEP coverage could avert up to 37,000 (22,000, 58,000) infections and cost US$300,000 (95% CI: US$162,000, US$667,000) per QALY gained. When coverage expansions are allowed to include combined investment with other programs and are compared to the next best intervention, the model projects that scaling OAT coverage up to 50%, then scaling NSP coverage to 50%, then scaling Test & Treat coverage to 50% can be cost-effective, with each coverage expansion having the potential to cost less than US$50,000 per QALY gained relative to the next best portfolio. In probabilistic sensitivity analyses, 59% of portfolios prioritized the addition of OAT and 41% prioritized the addition of NSPs, while PrEP was not likely to be a priority nor a cost-effective addition. Our findings are intended to be illustrative, as data on achievable coverage are limited and, in practice, the expansion scenarios considered may exceed feasible levels. We assumed independence of interventions and constant returns to scale. Extensive sensitivity analyses allowed us to assess parameter sensitivity, but the use of a dynamic compartmental model limited the exploration of structural sensitivities. CONCLUSIONS: We estimate that OAT, NSPs, and Test & Treat, implemented singly or in combination, have the potential to effectively and cost-effectively prevent HIV in US PWID. PrEP is not likely to be cost-effective in this population, based on the scenarios we evaluated. While local budgets or policy may constrain feasible coverage levels for the various interventions, our findings suggest that investments in combined prevention programs can substantially reduce HIV transmission and improve health outcomes among PWID.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Bernard CL, Owens DK, Goldhaber-Fiebert JD, et al. Estimation of the cost-effectiveness of HIV prevention portfolios for people who inject drugs in the United States: A model-based analysis. PLoS Med. 2017. PMID: 28542184. doi:10.1371/journal.pmed.1002312

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。